Brofaromine
Overview of the antidepressant drug Brofaromine
| Brofaromine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA) that was developed as an antidepressant and anxiolytic agent. It belongs to the class of monoamine oxidase inhibitors (MAOIs), which are used to treat depression by increasing the levels of neurotransmitters in the brain.
Mechanism of Action[edit | edit source]
Brofaromine works by selectively inhibiting the enzyme monoamine oxidase A (MAO-A). This enzyme is responsible for breaking down monoamines such as serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, brofaromine increases the availability of these neurotransmitters, which can help alleviate symptoms of depression and anxiety.
Pharmacokinetics[edit | edit source]
Brofaromine is absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism. It has a relatively short half-life, which allows for reversible inhibition of MAO-A, reducing the risk of hypertensive crisis associated with traditional MAOIs.
Clinical Use[edit | edit source]
Brofaromine was investigated for the treatment of major depressive disorder and anxiety disorders. However, it was never marketed due to the development of newer antidepressants with more favorable side effect profiles.
Side Effects[edit | edit source]
Common side effects of brofaromine include nausea, headache, and insomnia. Unlike traditional MAOIs, brofaromine has a lower risk of causing tyramine-induced hypertensive crisis, allowing for a less restrictive diet.
Development and History[edit | edit source]
Brofaromine was developed in the 1980s and underwent clinical trials to assess its efficacy and safety. Despite promising results, it was not brought to market, partly due to the emergence of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants that offered similar benefits with fewer dietary restrictions and side effects.
Related pages[edit | edit source]
Brofaromine
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
